等待开盘 11-07 09:30:00 美东时间
+0.196
+0.73%
Replimune Group announced the commercial availability of TUDRIQEV for advanced melanoma in the U.S., with early adoption by leading institutions. The company reported strong financials, including $307.8 million in cash, and highlighted successful early launch efforts and broad payer coverage. TUDRIQEV is indicated for use after PD-1 therapy failure and has shown promising clinical results in ongoing trials. The company remains focused on expandin...
10-28 11:00
T. Rowe Price核心美国股票主动型ETF跌13.19%,报24.49美元
09-08 09:42
TACU and TACN offer U.S. and international equity exposure with a 13-month fee waiver, combining active management and cost-efficient ETF structure.
2025-12-19 05:41
T. Rowe Price Group (TROW) expanded its suite of active exchange-traded fund with two new equity funds, the asset manager said on Thursday. The new ETFs -- T. Rowe Price Active Core U.S. Equity ETF (T...
2025-12-11 23:34